Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2019 - 2023)

Rocket Pharmaceuticals has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 34.39% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 0.9% YoY) and the FY2025 annual result came in at $8.9 million, up 22.85% from the prior year.
• Depreciation & Amortization (CF) declined to $1.6 million in Q1 2026 per RCKT's latest filing, from $1.7 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.7 million in Q3 2025 and troughed at $800000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) jumped 53.69% in 2024, then sank 34.39% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then surged by 39.6% to $1.4 million in 2023, then jumped by 30.52% to $1.8 million in 2024, then dropped by 7.9% to $1.7 million in 2025, then dropped by 4.17% to $1.6 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.6 million, $1.7 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.